Surgical Treatment Strategy with Combined Cardiopulmonary Bypass for Renal Cell Carcinoma with Tumor Embolism Developed in Inferior Vena Cava
Objective: Renal cell carcinoma (RCC) with tumor thrombus in the inferior vena cava (IVC) presents surgeons with a technical intraoperative challenge because of the need for aggressive surgical management. In this study, we describe our method for surgical management with cardiopulmonary bypass (CPB) and investigate the long-term outcomes of RCC patients with and without CPB.
Methods: Fifteen patients with RCC underwent nephrectomy and IVC thrombectomy from May 2011 to December 2017. We retrospectively reviewed and analyzed the clinical course of all patients. Novick classification was used to assess the level of tumor thrombus extension into the IVC. Patient characteristics, surgical procedures, and postoperative outcome data in both groups were collected.
Results: Twelve patients were male and 3 were female, with an average age of 62.9 ± 10.9 years (range 46 to 82). The average operative times were 824 ± 335 minutes in the patients with CPB and 646 ± 162 minutes in those without CPB (P = .17). The average amount of intraoperative bleeding was 2125 ± 1315 ml in the patients with CPB and 3333 ± 1431 ml in those without CPB (P = .14). The same tendency was observed in patients of Novick levels 3 and 4. The mean observation period was 1061.4 days. No 30-day mortality was noted. There was no significant difference in all-cause survival between the patients with CPB and those without.
Conclusions: We conclude that surgical management with CPB and circulatory arrest may be a viable and safe method of treatment for RCC patients.
Ali AS, Vasdev N, Shanmuganathan S, et al. 2013. The surgical management and prognosis of renal cell cancer with IVC tumor thrombus: 15-years of experience using a multi-specialty approach at a single UK referral center. Urol Oncol 31:1298-1304.
Bachmann A, Seitz M, Graser A, et al. 2005. Tumour nephrectomy with vena cava thrombus. BJU Int 95:1373-1384.
Belis JA, Levinson ME, Pae WE Jr. 2000. Complete radical nephrectomy and vena caval thrombectomy during circulatory arrest. J Urol 163:434-436.
Blute ML, Leibovich BC, Lohse CM, et al. 2004. The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus. BJU Int 94:33-41.
Carrascal Y, Gualis J, Arévalo A. 2008. Cardiac surgery with extracorporeal circulation in cancer patients: Influence on surgical morbidity and mortality and survival. Rev Esp Cardiol 61:369-375.
Chan F, Ngan Kee WD, Low JM. 2001. Anesthetic management of renal cell carcinoma with inferior vena caval extension. J Clin Anesth 13:585-587.
Chowdhury UK, Mishra AK, Seth A, et al. 2007. Novel techniques for tumor thrombectomy for renal cell carcinoma with intraatrial tumor thrombus. Ann Thorac Surg 83:1731-1736.
Ciancio G, Livingstone AS, Soloway M. 2007. Surgical management of renal cell carcinoma with tumor thrombus in the renal and inferior vena cava: The University of Miami experience in using liver transplantation techniques. Eur Urol 51:988-994.
Ciancio G, Manoharan M, Katkoori D, et al. 2010. Long-term survival in patients undergoing radical nephrectomy and inferior vena cava thrombectomy: Single-center experience. Eur Urol 57:667-672.
Ciancio G, Soloway MS. 2005. Renal cell carcinoma with tumor thrombus extending above diaphragm: avoiding cardiopulmonary bypass. Urology 66:266-270.
Dellaportas D, Arkadopoulos N, Tzanoglou I, et al. 2017. Technical intraoperative maneuvers for the management of inferior vena cava thrombus in renal cell carcinoma. Front Surg 4:48.
Dindo D, Demartines N, Clavien PA. 2004. Classification of surgical complications: A new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg 240:205-213.
Dominik J, Moravek P, Zacek P, et al. 2013. Long-term survival after radical surgery for renal cell carcinoma with tumour thrombus extension into the right atrium. BJU Int 111:E59-E64.
Fuhrman SA, Lasky LC, Limas C. 1982. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 6:655-663.
Janzen NK, Kim HL, Figlin RA, et al. 2003. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 30:843-852.
Jemal A, Siegel R, Xu J, et al. 2010. Cancer statistics, 2010. CA Cancer J Clin 60:277-300.
Kaplan S, Ekici S, Doğan R, et al. 2002. Surgical management of renal cell carcinoma with inferior vena cava tumor thrombus. Am J Surg 183:292-299.
Karnes RJ, Blute ML. 2008. Surgery insight: Management of renal cell carcinoma with associated inferior vena cava thrombus. Nat Clin Pract Urol 5:329-339.
Langer NB, Mercier O, Fabre D, et al. 2016. Outcomes after resection of T4 non-small cell lung cancer using cardiopulmonary bypass. Ann Thorac Surg 102:902-910.
Lawindy SM, Kurian T, Kim T, et al. 2012. Important surgical considerations in the management of renal cell carcinoma (RCC) with inferior vena cava (IVC) tumour thrombus. BJU Int 110:926-939.
Magouliotis DE, Tasiopoulou VS, Svokos AA, et al. 2018. Extracorporeal membrane oxygenation versus cardiopulmonary bypass during lung transplantation: A meta-analysis. Gen Thorac Cardiovasc Surg 66:38-47.
Marshall FF, Dietrick DD, Baumgartner WA, et al. 1988. Surgical management of renal cell carcinoma with intracaval neoplastic extension above the hepatic veins. J Urol 139:1166-1172.
Neves RJ, Zincke H. 1987. Surgical treatment of renal cancer with vena cava extension. Br J Urol 59:390-395.
Novick AC, Kaye MC, Cosgrove DM, et al. 1990. Experience with cardiopulmonary bypass and deep hypothermic circulatory arrest in the management of retroperitoneal tumors with large vena caval thrombi. Ann Surg 212:472-476; discussion 476-477.
Pinto CA, Marcella S, August DA, et al. 2013. Cardioplumonary bypass has a modest association with cancer progression: A retrospective cohort study. BMC Cancer 13:519.
Sablotzki A, Welters I, Lehmann N, et al. 1997. Plasma levels of immunoinhibitory cytokines interleukin-10 and transforming growth factor-beta in patients undergoing coronary artery bypass grafting. Eur J Cardiothorac Surg 11:763-768.
Shuch B, Crispen PL, Leibovich BC, et al. 2011. Cardiopulmonary bypass and renal cell carcinoma with level IV tumour thrombus: Can deep hypothermic circulatory arrest limit perioperative mortality? BJU Int 107:724-728.
Staehler G, Brkovic D. 2000. The role of radical surgery for renal cell carcinoma with extension into the vena cava. J Urol 163:1671-1675.
How to Cite
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).